Impel Pharmaceuticals Inc.
IMPL · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $10,212 | $30,140 | $33,145 | $89,022 |
| - Cash | $239 | $15,162 | $35,465 | $60,654 |
| + Debt | $114,798 | $52,295 | $52,905 | $51,186 |
| Enterprise Value | $124,771 | $67,273 | $50,585 | $79,554 |
| Revenue | $5,023 | $6,584 | $4,372 | $5,008 |
| % Growth | -23.7% | 50.6% | -12.7% | – |
| Gross Profit | $2,793 | $3,364 | $2,087 | $2,791 |
| % Margin | 55.6% | 51.1% | 47.7% | 55.7% |
| EBITDA | -$16,840 | -$16,104 | -$24,436 | -$5,709 |
| % Margin | -335.3% | -244.6% | -558.9% | -114% |
| Net Income | -$13,814 | -$7,357 | -$38,631 | -$36,312 |
| % Margin | -275% | -111.7% | -883.6% | -725.1% |
| EPS Diluted | -0.58 | -0.31 | -1.63 | -1.53 |
| % Growth | -87.1% | 81% | -6.5% | – |
| Operating Cash Flow | -$16,524 | -$20,440 | -$24,143 | -$17,986 |
| Capital Expenditures | -$957 | $132 | -$1,046 | -$1,012 |
| Free Cash Flow | -$17,481 | -$20,308 | -$25,189 | -$18,998 |